Q3 Round Up: The Going Stays Tough
The Evaluate team are back from the 2023 ASCO Annual Meeting reporting on all the big data drops and breakthroughs in cancer care.
Foreword
Slow Q3 For Biopharma M&A Boosted By Biogen/Reata
Biotech IPOs Get Bigger, But Not Necessarily Better
Q3 Shows Ongoing Venture Fundraising Challenges In Tough Financial Market
How we help